Brief: Moonlake Immunotherapeutics Reports Fourth Quarter And Year-End 2022 Financial Results And Provides A Business Update

MoonLake Immunotherapeutics

20/03/2023 11:57

March 20 (Reuters) - Moonlake Immunotherapeutics
 MLTX.O :
    * REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS
AND
PROVIDES A BUSINESS UPDATE
    * TOP-LINE RESULTS FOR A PHASE 2 TRIAL OF SONELOKIMAB IN
ACTIVE
PSA ANTICIPATED ON SCHEDULE AT THE END OF THE YEAR
    * QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO CONTROLLING
INTERESTS
SHAREHOLDERS $ 0.31
    * Q4 EARNINGS PER SHARE VIEW $-0.33 -- REFINITIV IBES DATA
    * TOP-LINE RESULTS FOR GLOBAL PHASE 2 TRIAL OF SONELOKIMAB
IN HS
EXPECTED AROUND END OF JUNE AND FINAL READ-OUT BY Q4

Source text for Eikon:  ID:nGNXbphJ5H 
Further company coverage:  MLTX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))